Related Experiment Video

Updated: May 15, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

Allan Joaquim Lamontanara1, Emel Basak Gencer, Orest Kuzyk

  • 1École polytechnique fédérale de Lausanne EPFL, School of Life Sciences, Swiss Institute for Experimental Cancer Research ISREC, Lausanne, Switzerland.

Biochimica Et Biophysica Acta
|January 2, 2013
PubMed

Insights

This review explores molecular mechanisms of kinase inhibitor resistance, focusing on BCR-ABL inhibitors like imatinib. It discusses next-generation drugs and alternative strategies for treating resistant cancers.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Kinase inhibitors are crucial in cancer therapy.
  • Resistance to targeted therapies like imatinib is a significant clinical challenge.
  • Understanding resistance mechanisms is key to developing effective treatments.

Purpose of the Study:

  • To review the molecular mechanisms of kinase inhibitor resistance.
  • To discuss imatinib resistance in BCR-ABL kinase.
  • To explore strategies for overcoming resistance in solid tumors.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of structural and mechanistic basis of imatinib resistance.
  • Discussion of next-generation inhibitors and alternative strategies.

Main Results:

  • BCR-ABL kinase is a primary target for imatinib.
  • Mutations in BCR-ABL lead to imatinib resistance.
  • Next-generation inhibitors and alternative strategies show promise.

Conclusions:

  • Molecular mechanisms of resistance vary but share commonalities.
  • Targeting resistance pathways is essential for durable cancer treatment.
  • Further research into resistance mechanisms will improve kinase inhibitor therapies.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: